We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $113M
1-Year Est. Return 245.92%
This Fund
S&P 500
This Quarter Est. Return
+23.08%
1 Year Est. Return
+245.92%
3 Year Est. Return
+826.04%
5 Year Est. Return
+770.7%
10 Year Est. Return
–
AUM
$124M
AUM Growth
+$27.8M
Cap. Flow
+$31.4M
Cap. Flow %
25.36%
Top 10 Hldgs %
54.69%
Holding
32
New
14
Increased
7
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
CMPS
Compass Pathways
CMPS
+$7.03M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$5.65M
3
CTMX icon
CytomX Therapeutics
CTMX
+$4.57M
4
ALMS
Alumis Inc
ALMS
+$4.17M
5
URGN icon
UroGen Pharma
URGN
+$4.05M

Top Sells

Rank Stock Value
1
ATAI icon
AtaiBeckley Inc
ATAI
+$7.01M
2
IVA
Inventiva
IVA
+$4.6M
3
ABVX
Abivax
ABVX
+$4.29M
4
TSHA icon
Taysha Gene Therapies
TSHA
+$2.51M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$980K

Sector Composition

Rank Sector Weight
1 Healthcare 81.3%
2 Miscellaneous 18.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
26
Relmada Therapeutics
RLMD
$462M
$1.47M 1.18%
+210,525
New +$996K
KPTI icon
27
CALL
Karyopharm Therapeutics
KPTI
$42.4M
$1.39M 1.12%
+250,000
New +$1.91M
ATAI icon
28
AtaiBeckley Inc
ATAI
$2.7B
– –
-1,713,105
Closed -$7.01M
CMPS
29
CALL
Compass Pathways
CMPS
$1.9B
– –
-1,100,000
Closed -$7.59M
EWTX icon
30
PUT
Edgewise Therapeutics
EWTX
$4.64B
– –
-250,000
Closed -$6.2M
TSHA icon
31
CALL
Taysha Gene Therapies
TSHA
$1.88B
– –
-500,000
Closed -$2.75M
TSHA icon
32
Taysha Gene Therapies
TSHA
$1.88B
– –
-457,132
Closed -$2.51M
1
2

Similar funds

IA
Invested Advisors State College, Pennsylvania $113M AUM 23.72% 1-Year Est. Return
CPA
Clear Point Advisors Melville, New York $113M AUM 15% 1-Year Est. Return
MBC
Michael Brady & Co Westlake, Ohio $113M AUM
OCM
Objective Capital Management Pepper Pike, Ohio $113M AUM 22.81% 1-Year Est. Return
AWA
Ark Wealth Advisors Yorba Linda, California $113M AUM
TWS
Thomas W. Smith $113M AUM
OFP
OFC Financial Planning Short Hills, New Jersey $113M AUM 26.89% 1-Year Est. Return
IIM
IFC & Insurance Marketing Auburn, California $114M AUM

Ally Bridge Group's Q1 2026 Portfolio in Review

As of Q1 2026, Ally Bridge Group held 32 positions worth $124M, up 29% from $96M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Ally Bridge Group deployed $31.4M of net new capital in Q1 2026, opening 14 new positions and adding to 7 existing holdings. Its largest new stake was Compass Pathways: 1,045,000 shares worth $5.78M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 66% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Inventiva, an estimated $4.6M trimmed.

  • Ally Bridge Group's largest Q1 2026 buy was Compass Pathways: 1,045,000 shares worth $5.78M.
  • Ally Bridge Group added most to Praxis Precision Medicines in Q1 2026, an estimated $4M increase.
  • Ally Bridge Group's biggest Q1 2026 reduction was Inventiva, cutting an estimated $4.6M.
  • Ally Bridge Group fully exited AtaiBeckley Inc in Q1 2026, selling an estimated $7.01M.
  • Ally Bridge Group's ten largest holdings make up 55% of its $124M portfolio in Q1 2026.
  • Ally Bridge Group opened 14 new positions and closed 5 in Q1 2026.
  • Ally Bridge Group's portfolio value rose 29% quarter-over-quarter to $124M.

Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.